Compare AMC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMC | DRTS |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Movies/Entertainment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.9M | 1.0B |
| IPO Year | 2007 | N/A |
| Metric | AMC | DRTS |
|---|---|---|
| Price | $2.83 | $11.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.03 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 49.9M | 660.8K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,848,900,000.00 | N/A |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $5.18 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $2.98 |
| 52 Week High | $3.26 | $14.11 |
| Indicator | AMC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 70.16 | 48.26 |
| Support Level | $1.66 | $11.51 |
| Resistance Level | $2.96 | $14.00 |
| Average True Range (ATR) | 0.23 | 0.89 |
| MACD | 0.07 | -0.24 |
| Stochastic Oscillator | 83.71 | 27.89 |
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.